Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 16/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622681 | 0.93 | FFAR4 (0.54) | FFAR4GAAKHKKDM4E | |
| Trifluoroacetic Acid SCHEMBL1024487 | 0.88 | KDM4E (0.56) | FFAR4FFAR1GAAKDM4E | |
| Trifluoroacetic Acid SCHEMBL4359200 | 0.87 | FFAR4 (0.47) | FFAR4FFAR1GAAKHKKDM4E | |
| Trifluoroacetic Acid SCHEMBL1025399 | 0.87 | GAA (0.60) | FFAR4FFAR1GAAKHKKDM4E | |
| Trifluoroacetic Acid SCHEMBL1022982 | 0.86 | FFAR4 (0.48) | FFAR4FFAR1GAAKHKKDM4E | |
| SCHEMBL1026537 | 0.84 | GAA (0.41) | FFAR4FFAR1GAAKDM4E | |
| SCHEMBL13622678 | 0.83 | KHK (0.48) | FFAR4FFAR1GAAKHKKDM4E | |
| Trifluoroacetic Acid SCHEMBL1024810 | 0.83 | FFAR4 (0.55) | FFAR4FFAR1 | |
| SCHEMBL13622686 | 0.82 | KDM4E (0.62) | FFAR4GAAKDM4E | |
| SCHEMBL13622662 | 0.79 | GAA (0.67) | FFAR4FFAR1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR4 2075/4885FFAR1 1611/4885GAA 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.